Lonza Group AG (LONN.SW) stock: key figures, P/E, revenue and dividend

Health Care · Switzerland · ISIN CH0013841017

Price
628.20 CHF
Market cap
43.99 bn CHF
P/E (2025)
46.46
P/S (2025)
6.74
Dividend yield
1.19 %
Net margin
-4.21 %
Return on equity (ROE)
-3.01 %
Return on assets (ROA)
-1.45 %

Lonza Group AG financials

Fiscal year20242025
Revenue5.48 bn CHF6.53 bn CHF
Gross profit2.16 bn CHF2.31 bn CHF
Operating income1.11 bn CHF1.40 bn CHF
EBIT964.00 m CHF1.38 bn CHF
Net income636.00 m CHF-275.00 m CHF
Diluted EPS – continuing operations8.58 CHF13.52 CHF

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.